The Triage Effectiveness of an Extended High-Risk Human Papillomavirus Genotyping Assay for Women with Cytology Showing Atypical Squamous Cells of Undetermined Significance in China
Overview
Affiliations
Purpose: Little is known about the performance of extended high-risk human papillomavirus (HR-HPV) genotyping triage of cytology showing atypical squamous cells of undetermined significance (ASC-US). This study aims to evaluate the effectiveness of triage with different HR-HPV genotype models among women with ASC-US.
Materials And Methods: In this study, all women who underwent cervical cytology and HR-HPV genotyping were enrolled from 2014 to 2017 in China, and those with cytology showing ASC-US were referred for colposcopy and/or biopsy. The endpoint was histological detection of cervical intraepithelial neoplasia grade 2 or worse (CIN2+). The outcome indicators were the sensitivity, specificity, positive predictive values (PPVs), negative predictive values (NPVs) and colposcopy referral rates.
Results: In all, 56,788 women were enrolled in this study, and 2658 (4.97%) women were reported to have ASC-US; 10.1% (242/2393) of women with ASC-US were identified as having CIN2+. The HR-HPV infection rate was 95.0% among all women with ASC-US who were identified as CIN2+, and the top five genotypes with prevalence and risk of CIN2+ were HPV16 (OR=26.38), HPV58 (OR=7.04), HPV18 (OR=4.44), HPV33 (OR=3.38), HPV31 (OR=2.97) and HPV52 (OR=2.96). The HPV16/18/31/33/52/58 model achieved higher sensitivity [91.3 (87.8-94.9)], specificity [70.0 (68.1-72.0)], PPV [25.5 (22.4-28.2)] and NPV [98.6 (97.3-98.7)] for the triage of ASC-US patients than the other HR-HPV-type combination models, but the colposcopy referral rate (36.2%) was significantly lower than that of the recommended HR-HPV nongenotyping model (47.6%).
Conclusion: This study confirms that the specific HR-HPV genotype HPV16/18/31/33/52/58 is an alternative strategy for ASC-US triage and can effectively reduce the high burden of colposcopy referrals in China.
Risk-based triage strategy by extended HPV genotyping for women with ASC-US cytology.
Rao X, Wang Y, Chen R, Wu Q, Zhang X, Fu Y Ann Med. 2025; 57(1):2451183.
PMID: 39823191 PMC: 11749152. DOI: 10.1080/07853890.2025.2451183.
Chen X, Jiang H, Xu H, Wang L, Liu P, Ma D BMC Cancer. 2024; 24(1):1385.
PMID: 39528979 PMC: 11556146. DOI: 10.1186/s12885-024-13082-z.
Cubaka Ntamushigo J, Motshedisi Sebitloane H Int J Gynaecol Obstet. 2024; 168(2):428-435.
PMID: 39268663 PMC: 11726148. DOI: 10.1002/ijgo.15915.
Ye Y, Jones T, Wang T, Zeng X, Liu Y, Zhao C Gynecol Obstet Clin Med. 2024; 4(1).
PMID: 38650896 PMC: 11034807. DOI: 10.1136/gocm-2024-000005.
Chua B, Lim L, Soon Yau Ng J, Ma Y, Wee H, Caro J Cancers (Basel). 2023; 15(6).
PMID: 36980698 PMC: 10046888. DOI: 10.3390/cancers15061812.